AMA 0076

Drug Profile

AMA 0076

Alternative Names: AMA-0076

Latest Information Update: 31 Jul 2015

Price : $50

At a glance

  • Originator Amakem
  • Class Antiglaucomas
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glaucoma; Ocular hypertension

Most Recent Events

  • 31 Jul 2015 Phase-II development is ongoing for Glaucoma and Ocular hypertension in USA
  • 01 Dec 2014 Amakem completes a phase IIa trial in Glaucoma or Ocular hypertension in USA (NCT02136940)
  • 30 Apr 2014 Amakem initiates enrolment in a phase IIa trial for Glaucoma or Ocular hypertension in USA (NCT02136940)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top